NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases. The Company's NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact; antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high-affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and Target-activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Type
Public
HQ
San Diego, US
Founded
2014
Size (employees)
118 (est)+27%
NantKwest was founded in 2014 and is headquartered in San Diego, US
Report incorrect company information

NantKwest Office Locations

NantKwest has an office in San Diego
San Diego, US (HQ)
3530 John Hopkins Ct
Show all (1)
Report incorrect company information

NantKwest Financials and Metrics

NantKwest Financials

NantKwest's revenue was reported to be $45 k in FY, 2017
USD

Revenue (Q1, 2018)

5 k

Net income (Q1, 2018)

(27.5 m)

EBIT (Q1, 2018)

(28.3 m)

Market capitalization (22-Jun-2018)

228.8 m

Closing share price (22-Jun-2018)

2.9

Cash (31-Mar-2018)

11.2 m
NantKwest's current market capitalization is $228.8 m.
Annual
USDFY, 2016FY, 2017

Revenue

44 k45 k

General and administrative expense

95.4 m57.1 m

R&D expense

29.2 m42 m

Operating expense total

124.5 m99.2 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

91 k10 k6 k12 k12 k11 k5 k

General and administrative expense

82.4 m38.9 m26.7 m28.6 m24.4 m16.2 m14.3 m

R&D expense

1.7 m4 m4.9 m6.4 m8.4 m9.2 m14 m

Operating expense total

84.2 m42.8 m31.6 m35 m32.8 m25.5 m28.3 m
Annual
USDFY, 2016FY, 2017

Cash

8.1 m23.9 m

Accounts Receivable

363 m

Current Assets

205.1 m132.5 m

PP&E

18.9 m76.7 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

120.4 m358.6 m63.3 m38.2 m31.4 m13.6 m11.2 m

Accounts Receivable

45 k145 k

Current Assets

120.9 m360.3 m225.5 m218 m214.5 m195.9 m126.8 m

PP&E

310 k1.4 m7.2 m9.5 m16.5 m22.6 m76.8 m
Annual
USDFY, 2016FY, 2017

Net Income

(120.8 m)(96.4 m)

Depreciation and Amortization

3.6 m5.6 m

Accounts Payable

888 k150 k

Cash From Operating Activities

(38.6 m)(48.8 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(84.6 m)(42.6 m)(30.7 m)(34 m)(31.9 m)(24.5 m)(27.5 m)

Depreciation and Amortization

1.6 m

Accounts Payable

3.2 m4.9 m1.1 m3.3 m2.2 m4.3 m117 k

Cash From Operating Activities

(15.5 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

NantKwest Online and Social Media Presence

Embed Graph
Report incorrect company information